Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukemia

NCT04803123 is registered in ClinicalTrials.gov with Dorothy Sipkins, MD, PhD as lead sponsor.

NCT NCT04803123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04803123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukemia
Lead sponsor
Dorothy Sipkins, MD, PhD
Phase
Phase 1
Overall status
Terminated
Start date
June 21, 2021
Completion date
April 26, 2023
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, acute lymphocytic